Iterum Therapeutics plc (NASDAQ:ITRM) price on Friday, October 08, rose 0.71% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.54.
A look at the stock’s price movement, the level at last check in today’s session was $0.53, moving within a range at $0.5215 and $0.5439. The beta value (5-Year monthly) was 1.25. Turning to its 52-week performance, $2.99 and $0.45 were the 52-week high and 52-week low respectively. Overall, ITRM moved -17.73% over the past month.
Iterum Therapeutics plc’s market cap currently stands at around $90.66 million, with investors looking forward to this quarter’s earnings report slated for Aug 04, 2021 – Aug 09, 2021. Analysts project the company’s earnings per share (EPS) to be $0.12, which has seen fiscal year 2021 EPS growth forecast to increase to -$0.28 and about -$0.23 for fiscal year 2022. Per the data, EPS growth is expected to be 87.00% for 2021 and 17.90% for the next financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that ITRM is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 2 analyst(s) rate the stock as a Hold, 0 recommend ITRM as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Hold which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ITRM’s current price about -6.96% and -17.91% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.40, while 7-day volatility ratio is 6.91% and 7.00% in the 30-day chart. Further, Iterum Therapeutics plc (ITRM) has a beta value of 1.27, and an average true range (ATR) of 0.04. Analysts have given the company’s stock an average 52-week price target of $1.75, forecast between a low of $1.00 and high of $2.50. Looking at the price targets, the low is -85.19% off recent price level in today’s trading while to achieve the yearly target high, it has to move -362.96%. Nonetheless, investors will most likely welcome a -224.07% jump to $1.75 which is the analysts’ median price.
In the market, a comparison of Iterum Therapeutics plc (ITRM) and its peers suggest the former has performed considerably stronger. Data shows ITRM’s intraday price has changed 0.71% today and -37.65% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.08% and -0.02% respectively on the day as seen in early trades.
If we refocus on Iterum Therapeutics plc (NASDAQ:ITRM), historical trading data shows that trading volumes averaged 10.8 million over the past 10 days and 7.37 million over the past 3 months. The company’s latest data on shares outstanding shows there are 180.02 million shares.
The 0.20% of Iterum Therapeutics plc’s shares are in the hands of company insiders while institutional holders own 11.20% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.91 million on May 27, 2021, giving us a short ratio of 0.33. The data shows that as of May 27, 2021 short interest in Iterum Therapeutics plc (ITRM) stood at 1.63% of shares outstanding, with shares short falling to 3.55 million registered in Apr 29, 2021. Current price change has pushed the stock -46.04% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ITRM stock continues to rise going into the next quarter.